TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32198301
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cell (MSC) therapy
Study: 33762031
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D sufficient (25(OH)D ≥ 30 ng/mL)
Study: 33762031
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels above 27.16-30.69 ng/mL
Study: 37767823
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BLT)
Study: 36753698
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day
Study: 33148481
Drug: Enalapril alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril alone (10 mg enalapril daily)
Study: 33852498
Drug: High-dose epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epidural fentanyl (≥100 μg)
Study: 36308037
Drug: Standardized skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized skin care regimen including once daily leave-on product application (lipid content 21%)
Study: 32394657
Drug: Warming acupuncture,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming acupuncture, 50 min each treatment, once daily, at the interval of 1 day after 4-day treatment, until ovulatory stage.
Study: 32394657
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received nuangong yunzi capsules, 3 capsules each time, three times a day, until ovulatory stage.
Study: 36083983
Drug: Outdoor residual
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outdoor residual spraying (ORS) with a capsule suspension of lambda-cyhalothrin for two days in October.
Study: 34887183
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural block (CEB) using 0.5 mg/kg of 0.125% bupivacaine (Marcaine)
Study: 32195729
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no additional treatment)
Study: 33743111
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of four serum miRNAs (miR-4257, miR-6785-5p, miR-187-5p, and miR-5739)
Study: 32805278
Drug: Health-related image
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health-related image included on dietary supplement packaging
Study: 35311937
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g in 100-mL intravenous bolus loading dose, followed by 1 g in 250-mL infusion within 8 hours of ICH onset)
Study: 36029489
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (0.25-0.5 mg/day) for eight weeks
Study: 34724213
Drug: 2.0% PVP-I
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0% PVP-I nasal spray
Study: 32646501
Drug: unripe Rubus
Normalized name: Rubus chamaemorus seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: unripe Rubus coreanus (uRC) 600 mg daily for 12 weeks
Study: 34170489
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for anorexia nervosa
Study: 33837377
Drug: Drugs targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs targeting IFNAR2
Study: 35246396
Drug: Intranasal low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal low-level laser therapy (LLLT)
Study: 35246396
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (AT)
Study: 32783178
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus endocrine therapy
Study: 32635503
Drug: Cod protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod protein hydrolysate (CPH), 4 g daily for 8 weeks
Study: 35864302
Drug: Cinnarizine 20
Normalized name: cinnarizine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 20 mg
Study: 33108633
Drug: Oral siponimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral siponimod 2 mg (initial dose titration over 6 days)
Study: 32557338
Drug: Stronger postoperative
Normalized name: Strongid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stronger postoperative analgesia (75/650 mg tramadol with paracetamol every 8 hours)
Study: 34031117
Drug: Thrice-weekly haemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly haemodialysis (standard HD group)
Study: 33902372
Drug: Paracetamol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg IV infusion
Study: 33902372
Drug: Pethidine 50
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 50 mg IV infusion
Study: 36383222
Drug: Drug-free DMN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free DMN
Study: 34226203
Drug: 6-week behaviour
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week behaviour change intervention (weekly sessions with a physiotherapist)
Study: 32615727
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent vehicle), administered for 12 weeks
Study: 32506861
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment with prednisone
Study: 35485939
Drug: Weekly digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly digital interventions assessing treatment adherence
Study: 32501212
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement appliance (MAA) therapy
Study: 33960006
Drug: Active repetitive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active repetitive transcranial magnetic stimulation (rTMS) with cognitive processing therapy (CPT+A)
Study: 33960006
Drug: Sham repetitive
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham repetitive transcranial magnetic stimulation (rTMS) with cognitive processing therapy (CPT+A)
Study: 34252909
Drug: Ketamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine treatment
Study: 34704480
Drug: Infliximab (anti-tumor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (anti-tumor necrosis factor antibody)
Study: 34704480
Drug: Antibiotics and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and/or seton drainage
Study: 34704480
Drug: Therapy directed
Normalized name: Chimeric Antigen Receptor immunotherapy directed against CLL-1 and CD33
DrugBank: CLL1-CD33 compound chimeric antigen receptor T cells (DB18568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy directed against intestinal inflammation
Study: 33393445
Drug: Lactulose 2
Normalized name: lactulose 2500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose 2 g/day for 2 weeks
Study: 35481712
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg daily for 3 months
Study: 35481712
Drug: conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional treatment (warfarin or rivaroxaban)
Study: 32807659
Drug: Hydrogel lenses
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel lenses in combination with silver cases
Study: 36216624
Drug: Extraction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction treatment (4 first premolars removed)
Study: 36216624
Drug: Nonextraction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonextraction treatment
Study: 36216624
Drug: Extraction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction treatment with minimal lip strain
Study: 32631388
Drug: AHE (Allium
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHE (Allium hookeri extract) 486 mg/day
Study: 39229471
Drug: Anticoagulants
Normalized name: ANTICOAGULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants
Study: 36318499
Drug: Narrative writing
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative writing intervention with resources and support from a narrative medicine facilitator
Study: 34731574
Drug: Conversation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversation group treatment (1 hr, twice per week, for 10 weeks)
Study: 32147071
Drug: Topical henna
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical henna preparation applied every night for two weeks
Study: 36315457
Drug: Medical-grade honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical-grade honey (MGH) applied intra-socket (L-Mesitran Soft)
Study: 32501985
Drug: High-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tirofiban (20 μg/kg)
Study: 32501985
Drug: Medium-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose tirofiban (10 μg/kg)
Study: 36006034
Drug: Gabapentin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (100 mg)
Study: 36006034
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mg lactose powder)
Study: 33160854
Drug: Tα1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tα1 treatment (1.6 mg subcutaneous injection for 15 days)
Study: 33160854
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (untreated, regular supportive treatment)
Study: 35022730
Drug: Ceftolozane/tazobactam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane/tazobactam (3 g, 2 g ceftolozane/1 g tazobactam q8h)
Study: 35022730
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g q8h)
Study: 35231769
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg EO-PGS
Study: 35231769
Drug: 0.75 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g/kg EO-PGS
Study: 32207659
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy defibrillators (CRT-D)
Study: 35254752
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TXA) with fluocinolone-based triple cream
Study: 34806244
Drug: Party and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Party and play use (methamphetamine, gamma-hydroxybutyrate, amyl nitrites, erectile dysfunction drugs)
Study: 32419092
Drug: Total effective
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total effective dose (FDT)
Study: 32419092
Drug: Total effective
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total effective dose (ABT)
Study: 32419092
Drug: Total effective
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total effective dose (MBT)
Study: 32419092
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of total effective doses among groups A, B, and C
Study: 36397128
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg/daily)
Study: 32067401
Drug: No Oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Oral Appliance (no OA)
Study: 36695874
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group A (TAD/HAM versus HAM/HAM ± G‐CSF followed by TAD and maintenance)
Study: 36695874
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group B (intermediate‐dose ara‐C/mitoxantrone followed by ara‐C/mitoxantrone)
Study: 33611761
Drug: High-dose methotrexate-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate-based chemotherapy with rituximab
Study: 39612621
Drug: (Neo)adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Neo)adjuvant chemotherapy
Study: 35010917
Drug: CIT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIT plus BR (3 g/kg/day of CIT plus 3 mg/kg/day of nitrates)
Study: 35010917
Drug: CIT (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIT (3 g/kg/day)
Study: 35010917
Drug: BR (3
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BR (3 mg/kg/day of NO3‐)
Study: 36045183
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy using an 830-nm LED device
Study: 33588594
Drug: Dabigatran (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (150 or 110 mg BID)
Study: 33588594
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg QD)
Study: 33017580
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms will provide step-up therapy of open-label amlodipine 5 mg if blood pressure is >140/90 at 6 weeks
Study: 32374030
Drug: FDC-2 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC-2 (10 mg macitentan/40 mg tadalafil)
Study: 35511451
Drug: Pressure-controlled ventilation-volume
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure-controlled ventilation-volume guaranteed (PCV-VG) with tidal volume set to 6 ml/kg and PEEP at 7 cm H2O
Study: 35511451
Drug: Volume controlled
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume controlled ventilation (VCV) with tidal volume set to 8 ml/kg
Study: 32965478
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable antipsychotics
Study: 37267732
Drug: Omega-3 supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplements
Study: 34438354
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2000 mg/day
Study: 36250938
Drug: Intravesical mitomycin-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical mitomycin-C (IMMC) 40 mg/20 mL, administered 1 day and 4 hours before TURBT
Study: 37441145
Drug: Intradermal acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal acupuncture (IA) treatment
Study: 35773113
Drug: Sedative use
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative use (pretreatment)
Study: 35773113
Drug: Cocaine use
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine use (initial 4 weeks of treatment)
Study: 35773113
Drug: Sedative use
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative use (initial 4 weeks of treatment)
Study: 34144282
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g EP/calf per day (ECL)
Study: 34144282
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g EP/calf per day (ECH)
Study: 34593565
Drug: Rucaparib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib monotherapy (600 mg orally twice a day)
Study: 34294036
Drug: Multimodal comprehensive
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal comprehensive care methodology training programme for family caregivers (6 hours total, three sessions of 2 hours each over 3 months, followed by weekly information delivery via postcard)
Study: 35559992
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of azithromycin (standard of care)
Study: 33961145
Drug: Renin-angiotensin blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin blockers
Study: 33062063
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab
Study: 36031718
Drug: 1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg ethanol
Study: 35255832
Drug: COLM-SST (caraway
Approvals — FDA: no, EMA: no, PMDA: no
Description: COLM-SST (caraway oil and L-menthol)
Study: 32121000
Drug: Unadjusted Hb
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unadjusted Hb cut-off <12 g/dL
Study: 33497295
Drug: Perineural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perineural bupivacaine infiltration (2 mL of 0.5% bupivacaine)
Study: 34633992
Drug: 0.5 mg·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg·kg‐1 ketamine for 40 minutes
Study: 33677450
Drug: Azilsartan 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan 20 mg daily for 3 months
Study: 33677450
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg daily for 3 months
Study: 35068500
Drug: Bepotastine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepotastine 10 mg tablet twice daily
Study: 35068500
Drug: Levocetirizine 5
Normalized name: Levocetirizine 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 5 mg tablet once daily
Study: 36203797
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (two capsules containing multi-strain probiotics daily)
Study: 35381194
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (<100 mmol or <1500 mg/day)
Study: 32740079
Drug: High-volume split-dose
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume split-dose PEG (2 L + 2 L)
Study: 34509641
Drug: Low-volume split-dose
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume split-dose PEG (1 L + 1 L) + bisacodyl (15 mg)
Study: 34036357
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g cheddar cheese
Study: 33476537
Drug: Total glucosides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total glucosides of paeony (TGP) treatment group
Study: 32812478
Drug: Pain neuroscience
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain neuroscience education (PNE), manual therapy (MT), and home exercise program (HEP)
Study: 32812478
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT) and home exercise program (HEP)
Study: 34362762
Drug: Automatic oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic oxygen titration using a novel nasal high-flow device
Study: 34362762
Drug: Manual oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual oxygen titration using nasal high flow
Study: 34362762
Drug: Automatic oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic oxygen titration
Study: 32539853
Drug: Immediate initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immediate initiation of pan-genotypic DAA treatment with individualized follow-up
Study: 39104653
Drug: Abrocitinib 200
Normalized name: abrocitinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrocitinib 200 mg
Study: 33859330
Drug: Galacto-oligosaccharides (GOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galacto-oligosaccharides (GOS) prebiotic supplement
Study: 32341247
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment at 20 mm Hg
Study: 36267207
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg)
Study: 33956130
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg biweekly)
Study: 33956130
Drug: Nivolumab (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (fixed dose of 240 mg biweekly or 480 mg monthly)
Study: 33243815
Drug: CAP256V2LS administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP256V2LS administered intravenously
Study: 33243815
Drug: CAP256V2LS+PGT121 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP256V2LS+PGT121 administered SC
Study: 33243815
Drug: CAP256V2LS+VRC07-523LS+PGT121 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP256V2LS+VRC07-523LS+PGT121 administered SC
Study: 34058717
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium diet (7000 mg/d)
Study: 34058717
Drug: Medium sodium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium sodium diet (2300 mg/d)
Study: 34058717
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (1000 mg/d)
Study: 35543540
Drug: 20 intradetrusor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 intradetrusor injections of onabotulinumtoxinA
Study: 32950829
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (30–50 mg·kg−1 intravenously as a bolus before induction, followed by 10–20 mg·kg−1 h−1 continuous infusion during surgery)
Study: 616351330
Drug: Liquid L‐T4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid L‐T4 formulation
Study: 616351330
Drug: Tablet form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet form L‐T4
Study: 33607177
Drug: Baricitinib (Jak1/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (Jak1/2 inhibitor), oral treatment for four weeks
Study: 36303868
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of white common bean extract (WCBE) taken half an hour before a meal (Group W)
Study: 36303868
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of maltodextrin as a placebo (Group C)
Study: 36303868
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of white common bean extract (WCBE) (Group W)
Study: 35068061
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + tamsulosin 0.4 mg once daily
Study: 34691317
Drug: Moxibustion plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion plus routine drug therapy